SG10201403758SA - Methods and compositions for use in cellular therapies - Google Patents
Methods and compositions for use in cellular therapiesInfo
- Publication number
- SG10201403758SA SG10201403758SA SG10201403758SA SG10201403758SA SG10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- cellular therapies
- therapies
- cellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22427509P | 2009-07-09 | 2009-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201403758SA true SG10201403758SA (en) | 2014-10-30 |
Family
ID=42782196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201403758SA SG10201403758SA (en) | 2009-07-09 | 2010-07-09 | Methods and compositions for use in cellular therapies |
| SG2012001574A SG177582A1 (en) | 2009-07-09 | 2010-07-09 | Methods and compositions for use in cellular therapies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012001574A SG177582A1 (en) | 2009-07-09 | 2010-07-09 | Methods and compositions for use in cellular therapies |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8679834B2 (en) |
| EP (2) | EP2451943B1 (en) |
| JP (1) | JP5892931B2 (en) |
| KR (1) | KR101788885B1 (en) |
| CN (2) | CN102549147A (en) |
| AU (1) | AU2010269962B2 (en) |
| BR (1) | BR112012000534A2 (en) |
| CA (1) | CA2767300C (en) |
| DK (1) | DK2451943T3 (en) |
| ES (1) | ES2479542T3 (en) |
| HU (1) | HUE031921T2 (en) |
| IL (1) | IL217377A (en) |
| MX (1) | MX359639B (en) |
| NZ (1) | NZ597975A (en) |
| PL (1) | PL2451943T3 (en) |
| PT (1) | PT2451943T (en) |
| RU (1) | RU2610427C2 (en) |
| SG (2) | SG10201403758SA (en) |
| WO (1) | WO2011004264A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| SG10201400793RA (en) | 2005-09-23 | 2014-08-28 | Cellerix Sl | Cell populations having immunoregulatory activity, method for isolation and uses |
| WO2011006029A1 (en) | 2009-07-10 | 2011-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Artificial cell constructs for inducing immunological tolerance |
| US11090363B2 (en) | 2009-07-10 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Vasoactive intestinal peptide release from microparticles |
| EP2663316A2 (en) * | 2011-01-12 | 2013-11-20 | TiGenix, S.A.U. | Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases |
| WO2013149211A2 (en) * | 2012-03-30 | 2013-10-03 | University Of Southern California | Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation |
| WO2016098061A1 (en) | 2014-12-18 | 2016-06-23 | Pluristem Ltd. | Methods and compositions for treating and preventing muscle wasting disorders |
| WO2016107563A1 (en) * | 2014-12-29 | 2016-07-07 | 西比曼生物科技（上海）有限公司 | Fatty mesenchymal progenitor cell complex for treating upper respiratory tract illnesses |
| WO2016151476A1 (en) | 2015-03-23 | 2016-09-29 | Pluristem Ltd. | Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof |
| CA3012741A1 (en) | 2016-02-18 | 2017-08-24 | Pluristem Ltd. | Methods and compositions for treating cancer and neoplasms |
| GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| US11510946B2 (en) | 2017-05-15 | 2022-11-29 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with adipose-derived stem cells |
| CA3062964A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells |
| CN107281469A (en) * | 2017-07-17 | 2017-10-24 | 广东颜值科技有限公司 | A kind of cell composition and its preparation method and application |
| CN107349419A (en) * | 2017-07-17 | 2017-11-17 | 广东颜值科技有限公司 | A kind of cell composition and its preparation method and application |
| EP3851112A4 (en) * | 2018-09-14 | 2022-07-27 | Luca Science Inc. | Transplantation of mitochondria into lymphoid organ and composition therefor |
| JP2022527455A (en) * | 2019-03-19 | 2022-06-02 | フィジーン、エルエルシー | Treatment of Chronic Obstructive Pulmonary Disease and Pulmonary Degeneration with Activated Fibroblasts and Their Exosome Derivatives |
| US11878037B2 (en) | 2019-05-31 | 2024-01-23 | Figene, Llc | Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis |
| US20240000850A1 (en) * | 2020-04-08 | 2024-01-04 | Figene, Llc | Methods and compositions for allergy and asthma treatment using fibroblasts |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004006951A1 (en) * | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| DK1567155T3 (en) * | 2002-12-06 | 2011-02-14 | Northwest Biotherapeutics Inc | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| SG10201400793RA (en) | 2005-09-23 | 2014-08-28 | Cellerix Sl | Cell populations having immunoregulatory activity, method for isolation and uses |
| US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
| AU2008287063B2 (en) * | 2007-08-09 | 2013-10-24 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| EP2191835A4 (en) * | 2007-09-07 | 2011-12-14 | Japan Chem Res | Therapeutic and prophylactic agents for arthritis |
| US20110150845A1 (en) * | 2008-05-02 | 2011-06-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating immunological tolerance |
| GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
-
2010
- 2010-07-09 NZ NZ597975A patent/NZ597975A/en unknown
- 2010-07-09 PT PT107521718T patent/PT2451943T/en unknown
- 2010-07-09 US US13/382,426 patent/US8679834B2/en active Active
- 2010-07-09 CN CN2010800308900A patent/CN102549147A/en active Pending
- 2010-07-09 RU RU2012104529A patent/RU2610427C2/en active
- 2010-07-09 SG SG10201403758SA patent/SG10201403758SA/en unknown
- 2010-07-09 AU AU2010269962A patent/AU2010269962B2/en active Active
- 2010-07-09 KR KR1020127003364A patent/KR101788885B1/en active IP Right Grant
- 2010-07-09 ES ES10752171.8T patent/ES2479542T3/en active Active
- 2010-07-09 WO PCT/IB2010/001968 patent/WO2011004264A1/en active Application Filing
- 2010-07-09 EP EP10752171.8A patent/EP2451943B1/en active Active
- 2010-07-09 EP EP16199980.0A patent/EP3150703A1/en not_active Withdrawn
- 2010-07-09 MX MX2012000396A patent/MX359639B/en active IP Right Grant
- 2010-07-09 JP JP2012519080A patent/JP5892931B2/en active Active
- 2010-07-09 BR BR112012000534A patent/BR112012000534A2/en not_active Application Discontinuation
- 2010-07-09 PL PL10752171T patent/PL2451943T3/en unknown
- 2010-07-09 CA CA2767300A patent/CA2767300C/en active Active
- 2010-07-09 DK DK10752171.8T patent/DK2451943T3/en active
- 2010-07-09 SG SG2012001574A patent/SG177582A1/en unknown
- 2010-07-09 HU HUE10752171A patent/HUE031921T2/en unknown
- 2010-07-09 CN CN201710067652.0A patent/CN107007626A/en active Pending
-
2012
- 2012-01-05 IL IL217377A patent/IL217377A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX359639B (en) | 2018-10-04 |
| EP3150703A1 (en) | 2017-04-05 |
| RU2012104529A (en) | 2013-08-20 |
| IL217377A0 (en) | 2012-02-29 |
| HUE031921T2 (en) | 2017-08-28 |
| KR101788885B1 (en) | 2017-10-20 |
| AU2010269962A1 (en) | 2012-03-01 |
| JP5892931B2 (en) | 2016-03-23 |
| MX2012000396A (en) | 2012-07-17 |
| RU2610427C2 (en) | 2017-02-10 |
| WO2011004264A1 (en) | 2011-01-13 |
| DK2451943T3 (en) | 2017-02-06 |
| KR20120051006A (en) | 2012-05-21 |
| EP2451943B1 (en) | 2016-11-23 |
| US8679834B2 (en) | 2014-03-25 |
| BR112012000534A2 (en) | 2017-06-13 |
| CN102549147A (en) | 2012-07-04 |
| JP2012532859A (en) | 2012-12-20 |
| EP2451943A1 (en) | 2012-05-16 |
| IL217377A (en) | 2017-10-31 |
| US20120308585A1 (en) | 2012-12-06 |
| CA2767300C (en) | 2020-01-07 |
| AU2010269962B2 (en) | 2016-04-14 |
| PT2451943T (en) | 2017-01-20 |
| SG177582A1 (en) | 2012-03-29 |
| ES2479542T3 (en) | 2017-05-26 |
| PL2451943T3 (en) | 2017-04-28 |
| CA2767300A1 (en) | 2011-01-13 |
| ES2479542T1 (en) | 2014-08-20 |
| NZ597975A (en) | 2014-06-27 |
| CN107007626A (en) | 2017-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201403758SA (en) | Methods and compositions for use in cellular therapies | |
| PT2272339E (en) | Methods and compositions for use with gel dispensers | |
| HK1172401A1 (en) | Materials for use in ophthalmic applications and methods | |
| EP2536293A4 (en) | Methods and compositions for use in aquaculture | |
| HRP20181380T1 (en) | Lipopeptide compositions and related methods | |
| IL218212A0 (en) | Therapeutic methods and compositions | |
| ZA201206718B (en) | Pde10 inhibitors and related compositions and methods | |
| EP2629742A4 (en) | Hair-mending compositions and associated methods | |
| IL214500A0 (en) | Compositions and methods for extended therapy with aminopyridines | |
| ZA201202561B (en) | Compositions and methods for enhancing cognitive and related functions in animals | |
| GB0903299D0 (en) | Composition and methods | |
| EP2410990A4 (en) | Compositions and methods for enhancing contrast in imaging | |
| EP2601269A4 (en) | Anti-settling compositions and methods for use | |
| EP2205271A4 (en) | Compositions and methods for ribonuclease-based therapies | |
| HK1201451A1 (en) | Compositions and methods | |
| GB201018650D0 (en) | Methods and compositions | |
| GB0901494D0 (en) | Compositions and Methods | |
| ZA201305086B (en) | Methods and compositions useful for promoting sleep in animals | |
| EP2461870A4 (en) | Therapeutic compositions and methods | |
| EP2504065A4 (en) | Stable mixtures and related methods | |
| GB2475090B (en) | Fuels, methods of making them and additives for use in fuels | |
| EP2498606A4 (en) | Tivozanib and temsirolimus in combination | |
| ZA201201369B (en) | Improvements in and relating to cable-barriers | |
| EP2723349A4 (en) | Microrna-31 compositions and methods for use in autoimmune disease | |
| GB0900329D0 (en) | Improvements in anti-ligature devices and methods |